DIA global headquarters will host 18 leaders from the State Food and Drug Administration of China (SFDA). The SFDA delegation is comprised of leaders from different provinces of China as well as four individuals from the central office in Beijing. Their expertise includes drug registration and the center of control testing labs.
Prior to their arrival at DIA, the group participated in a 10-day regulatory affairs training at Yale University’s School of Public Health. Since completing the program earlier this week, the delegation has been visiting various organizations such as the NJ FDA Field Office, Novartis, the University of Sciences Philadelphia, and the United States Pharmacopeia (USP). SFDA participants include:
“DIA is a global community that shares knowledge, cultivates relationships, and facilitates dialogue among regulators across and within all geographic regions,” says Paul Pomerantz, DIA Worldwide Executive Director.” We are pleased to welcome representatives from SFDA to our global headquarters to explore how our organizations can continue to work together to educate our industry about reporting, compliance and other requirements and developments around the world.”
In addition, three executive team members from the Sino-American Pharmaceutical Professionals Association of Greater Philadelphia (SAPA GP) will be in attendance.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.